Q3 2026 AtriCure, Inc. Earnings Conference Call - ATRICURE INC

Explicit Guidance:

• FY2026 Revenue: Raised to $606 million – $610 million, representing 13.4% – 14.1% year-over-year growth.
• FY2026 Adjusted EBITDA: Raised to $91 million – $94 million.
• FY2026 Net Income: Reiterated expectation (no specific range provided, confirmed ahead of initial guidance).
• FY2026 Earnings Per Share (EPS): Approximately $0.21 – $0.27.
• FY2026 Adjusted EPS: Approximately $0.40 – $0.46.
• FY2026 Gross Margin: Expected in the upper 76% range, with potential quarter-to-quarter variability due to mix.
• Q4 2026 Outlook: Guidance reflects prudence amidst international headwinds and U.S. hybrid ablation pressure; sequential EPS step-down expected due to R&D investment acceleration.

Business-Segment Outlook:

• Open Ablation: Continued strong adoption driven by Encompass clamp (now >70% of US open ablation revenue); anticipated further growth via STS quality metrics (targeting 70% treatment rate) phased in over the next 1–2 years.
• Appendage Management: LAX-2 and LEAPS trials (6,500+ patients) expected to drive significant growth; 30mm Atriclip Flex Mini launching December 2026; Atriclip Flex Mini V targeted for late 2027 launch.
• Pain Management: CryoSphere Max driving steady growth; Cryo XT sales surpassed 1,000 units, expected to accelerate in 2027 and see significant ramp in 2028; sternotomy market penetration currently mid-single digits with gradual growth expected.
• Minimally Invasive Ablation (MIS): Headwinds persist due to market shift toward PFA catheter therapy; company remains committed to hybrid AF therapy strategy.
• Clinical Catalysts: BOXx NOAAF enrollment >880 patients (target <100 remaining) to complete end-of-year; primary endpoint readout expected Spring 2027; BOXx PMA approval anticipated mid-2028.

Market and Competitive Outlook:

• Quality Metrics: New STS quality metric for concomitant AFib treatment expected to drive broader adoption of surgical ablation and LAA management over several years; initial rollout is a "phase" approach rather than immediate mandate.
• Competitive Landscape: Introduction of 30mm Atriclip Flex Mini differentiates platform against competitors (typically 35mm+); company views new competition as creating market awareness while leveraging superior clinical evidence (LAX-2, LEAPS, LAOS-3).
• Sales Force: Current footprint ~350 personnel in cardiac surgery; planned expansion in 2027 to prepare for BOXx data-driven acceleration in 2028.

Macro / Industry Outlook:

• Geographic Trends: U.S. business outperforming international markets; international growth slowed by execution challenges in newer European teams and specific reimbursement headwinds (e.g., CryoSphere in UK).
• Economic Factors: No specific FX or tariff guidance; international growth outlook remains constrained through remainder of 2026, with optimism for recovery and return to historical growth rates as teams mature and new products (e.g., Encompass in Europe) gain traction.

Strategic Initiatives:

• R&D Investment: FY2027 R&D spending focused on dual-energy Encompass device (RF + PFA) requiring new IDE-level trials; continued follow-up on BOXx (3-year AFib recurrence) and LEAPS; expanded investigator studies for Cryo Nerve Lock.
• Product Launches: 30mm Atriclip Flex Mini (Dec 2026); Atriclip Flex Mini V (Late 2027); BOXx commercialization and PMA approval (Mid-2028).
• Manufacturing: New facility costs incurred; full-year gross margin impact expected to normalize as U.S. revenue mix increases and volume scales.

Risks and Headwinds to Outlook:

• International Markets: Sustained headwinds in Europe (funding, reimbursement) and slower-than-expected adoption rates in non-US markets through end of 2026.
• U.S. Hybrid Ablation: Continued market pressure from PFA catheter therapy limiting MIS ablation growth.
• Clinical Delays: Potential delays in BOXx/LEAPS data publication or regulatory (FDA) approval timelines beyond mid-2028.
• Regulatory/Guideline Pace: Clinical guidelines may lag PMA approval; adoption of quality metrics is expected to be phased, not immediate.
• Margin Variability: Gross margin fluctuations driven by geographic/product mix and incremental costs from new manufacturing facility.

Management Tone on the Future:

• Confidence Level: High confidence in long-term growth opportunities and ability to outpace long-range targets set in early 2025; momentum described as "strong" and "durable."
• Hedges: Explicitly noted prudence in Q4 guidance to ensure a pathway to beats despite strong Q3 performance; cautious regarding international recovery timing.
• Strategic Focus: Emphasis on clinical evidence (BOXx, LEAPS, LAX-2) as the primary growth catalyst for the next phase of expansion.

Miscellaneous:

• Share Count/Dividends: No specific guidance on share count, dividends, or buybacks provided in this transcript.
• Capex: Incremental costs from new manufacturing facility noted as a headwind to Q3 gross margin, but expected to be offset by volume and mix improvements long-term.